- Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
- Harrow Announces First Quarter 2023 Financial Results
- Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
- Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
- Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
- Harrow Announces New $100 Million Secured Credit Facility with Oaktree
- Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
- Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
- Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
More ▼
Key statistics
On Friday, Harrow Health Inc (HROW:NMQ) closed at 19.56, -30.76% below its 52-week high of 28.25, set on May 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.71 |
---|---|
High | 19.71 |
Low | 19.08 |
Bid | 18.41 |
Offer | 20.20 |
Previous close | 19.51 |
Average volume | 555.67k |
---|---|
Shares outstanding | 30.12m |
Free float | 25.25m |
P/E (TTM) | -- |
Market cap | 589.19m USD |
EPS (TTM) | -0.6465 USD |
Data delayed at least 15 minutes, as of Jun 02 2023 21:00 BST.
More ▼